Walleye Capital LLC Takes $511,000 Position in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Walleye Capital LLC has acquired a new position in Maravai LifeSciences Holdings, purchasing 231,000 shares worth approximately $511,000.
• Numerous institutional investors have adjusted their stakes in Maravai, with hedge funds collectively owning 50.25% of the company's stock.
• Analyst ratings have been mixed for Maravai LifeSciences, with three "Buy," seven "Hold," and one "Sell" rating, and an average price target of $5.22.

Walleye Capital LLC bought a new stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 231,000 shares of the company's stock, valued at approximately $511,000. Walleye Capital LLC owned about 0.09% of Maravai LifeSciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MRVI. EntryPoint Capital LLC purchased a new position in shares of Maravai LifeSciences during the first quarter worth $32,000. Teacher Retirement System of Texas acquired a new position in Maravai LifeSciences during the 1st quarter worth about $37,000. Aigen Investment Management LP purchased a new position in Maravai LifeSciences during the 1st quarter valued at about $37,000. Performa Ltd US LLC boosted its holdings in Maravai LifeSciences by 245.0% during the 1st quarter. Performa Ltd US LLC now owns 17,250 shares of the company's stock valued at $38,000 after acquiring an additional 12,250 shares during the period. Finally, Pekin Hardy Strauss Inc. acquired a new position in Maravai LifeSciences in the 1st quarter valued at about $55,000. Hedge funds and other institutional investors own 50.25% of the company's stock.

Analyst Ratings Changes

MRVI has been the topic of several research reports. Royal Bank Of Canada reduced their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 12th. Craig Hallum reduced their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, Robert W. Baird dropped their price target on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Three analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of "Hold" and a consensus target price of $5.22.

Maravai LifeSciences Stock Up 6.4%

Maravai LifeSciences stock traded up $0.15 during trading on Friday, reaching $2.51. The stock had a trading volume of 1,148,421 shares, compared to its average volume of 1,142,170. The company has a quick ratio of 4.49, a current ratio of 5.16 and a debt-to-equity ratio of 0.68. Maravai LifeSciences Holdings, Inc. has a 52-week low of $1.66 and a 52-week high of $9.60. The stock has a market cap of $640.95 million, a PE ratio of -1.85 and a beta of 0.29. The business has a 50 day moving average price of $2.49 and a 200 day moving average price of $2.36.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.